REG - Immupharma PLC - Incanthera provides Comm'l Update/Revenue F'casts

ImmuPharmaAnnouncement

25/03/2024 07:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240325:nRSY1214Ia&default-theme=true

RNS Number : 1214I  Immupharma PLC  25 March 2024

25 March 2024

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Incanthera Provides Commercial Update

and Revenue Forecasts

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is delighted to highlight the announcement issued this morning by
Incanthera plc ("Incanthera"), the dermatology and oncology specialist, in
which ImmuPharma currently holds a 10.8% shareholding.

 

Within the announcement, Incanthera announces an update on its commercial
skincare deal, announced in December 2023, with Marionnaud (part of the A.S.
Watson Group).

 

Under the terms of the deal, Skin + CELL will be initially launched in c. 100
of Marionnaud's stores in Switzerland and Austria, followed by a planned
roll out into the remaining 1,100 European stores, with subsequent anticipated
roll outs into major Asian markets.

 

Incanthera has announced that the first order from Marionnaud has now doubled
from 25,000 units to 50,000 units due to the strong demand anticipated by
Marionnaud's management and that this first order, on track to be delivered
during Q2 2024, will generate c. £2m revenue for Incanthera.

 

Incanthera also confirms that it projects revenues of £10m and profitability,
for the financial year ("FY") to 31 March 2025, growing to revenues of £33m
and increased profitability, in the following FY to 31 March 2026.

 

More insight into Incanthera's technology and deal with Marionnaud is
illustrated through the initiation of a Research Note by Stanford Capital
Partners, which will shortly be available on the Incanthera plc website
www.incanthera.com (http://www.incanthera.com) .

 

Incanthera trades on Aquis Stock Exchange ("AQSE") under the ticker
(AQSE:INC). For full details of the announcement, please visit Incanthera's
website: https://incanthera.com/investors/regulatory-news/
(https://incanthera.com/investors/regulatory-news/) .

 

Commenting on Incanthera's announcement, Dr Tim Franklin, COO of ImmuPharma
said: "As a major shareholder in Incanthera, we are delighted with this
further progress and in particular Incanthera's revenue momentum and move into
profitability. This highlights the strong financial asset we have in
Incanthera and the enormous opportunities within the company's revolutionary
skincare range and its partnership with Marionnaud."

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Dr Tim Franklin, COO

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650/51

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in
dermatology and oncology. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs, utilising
new technology from leading specialists and academic institutions as well as
its in-house development team.

 

Incanthera originated from the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford.  Incanthera's strategy is to develop each
candidate in its portfolio from initial acquisition or discovery to securing
its future through commercially valuable partnerships at the earliest
opportunity in its development pathway.

 

For more information on Incanthera please visit: www.incanthera.com
(http://www.incanthera.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSEDSWIELSEED